ICU Medical, Inc. appears in FDA device records in two distinct roles. As an applicant, it received a substantially equivalent decision on K260478 for CleanBreak™, an intravenous catheter force-activated separation device in product code QOI, regulation 880.5220, under the General Hospital advisory committee. As a recalling firm, it is named on four cited Class II enforcement records initiated in May 2026 concerning intravascular administration tubing sets with drip chambers. The company also files quarterly and annual reports with the Securities and Exchange Commission, and its own website describes an IV Performance Platform. [1][2][3][4][5][7][8][9]
The CleanBreak™ clearance
FDA record K260478 lists ICU Medical, Inc. of San Clemente, California as applicant for CleanBreak™, with the openFDA device name Intravenous Catheter Force-Activated Separation Device. The submission was received February 13, 2026, and decided November 6, 2026, with decision code SESE and the description Substantially Equivalent. The clearance type is Traditional, the third-party review flag is No, and the statement or summary field reads Summary. [1]
The FDA 510(k) database page for K260478 restates the substantially equivalent decision, the General Hospital regulation and review panel, the Traditional type, and that the filing was not reviewed by a third party and is not a combination product. The page records that no predetermined change control plan was authorized and shows a last-updated date of November 16, 2026. [6]
Administration set recalls
Four enforcement records name ICU Medical, Inc. as recalling firm for products with drip chambers: IV Sets with drip chambers (Z-3160-2026), Oncology sets with drip chambers (Z-3159-2026), Plum administration sets (Z-3156-2026), IV Non-Dedicated Gravity Administration Sets with drip chambers (Z-3157-2026). Each is classified Class II, voluntary and firm initiated, with a recall initiation date of May 12, 2026, a center classification date of September 11, 2026, and a status of Ongoing. [2][3][4][5]
The FDA reason statements differ in an important detail. Z-3160-2026 and Z-3156-2026 describe black specks potentially associated with PVC molding and state that discoloration or particulate matter in the fluid path has not been ruled out. Z-3159-2026 and Z-3157-2026 describe discolored PVC in the chamber wall that does not enter the fluid path, with possible product replacement before use and a resulting delay in therapy. These are the respective notices’ descriptions, rather than a single conclusion applied to every administration set. [2][3][4][5]
Recorded quantities and scope
The enforcement records state differing product quantities: 28,550 for the oncology sets, 163,500,199 for the Plum administration sets, and 2,450 for the IV non-dedicated gravity administration sets. Each record lists UDI-DI identifiers for the affected products and identifies the initial firm notification as a press release. These figures describe the recalled lots in those filings and are not measures of company sales or total product volume. [3][4][5]
The linked FDA collection for this profile contains one 510(k) record, with a decision count of one substantially equivalent decision, and the sampled record set likewise contains that single 510(k) entry. The recall records appear as a separate sample and are not counted in those 510(k) totals. [1][2][3][4][5]
Corporate documentation
ICU Medical, Inc. is incorporated in Delaware with Commission File No. 001-34634, and its Form 10-Q for the quarterly period ended September 30, 2026 was filed November 5, 2026, with Vivek Jain identified as Chief Executive Officer in the accompanying certification. The Form 10-K for the fiscal year ended December 31, 2025 was filed February 19, 2026, and lists subsidiaries including EXC Holding Corp. The SEC filings give a street address at 951 Calle Amanecer, the same street address appearing in the FDA records. [8][9][1]
ICU Medical's own website describes an IV Performance Platform and states that its information is intended for healthcare professionals only. That page is the manufacturer's published documentation and does not establish clinical performance. [7]




